DK4021487T5 - Antigene peptider til forebyggelse og behandling af b-celle malignitet - Google Patents
Antigene peptider til forebyggelse og behandling af b-celle malignitet Download PDFInfo
- Publication number
- DK4021487T5 DK4021487T5 DK20804279.6T DK20804279T DK4021487T5 DK 4021487 T5 DK4021487 T5 DK 4021487T5 DK 20804279 T DK20804279 T DK 20804279T DK 4021487 T5 DK4021487 T5 DK 4021487T5
- Authority
- DK
- Denmark
- Prior art keywords
- prevention
- treatment
- antigenic peptides
- cell malignancy
- malignancy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001124—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19306475 | 2019-11-15 | ||
| EP2020079257 | 2020-10-16 | ||
| PCT/EP2020/082101 WO2021094562A2 (en) | 2019-11-15 | 2020-11-13 | Antigenic peptides for prevention and treatment of b-cell malignancy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK4021487T3 DK4021487T3 (da) | 2024-02-12 |
| DK4021487T5 true DK4021487T5 (da) | 2024-07-29 |
Family
ID=75911928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20804279.6T DK4021487T5 (da) | 2019-11-15 | 2020-11-13 | Antigene peptider til forebyggelse og behandling af b-celle malignitet |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11759508B2 (enExample) |
| EP (2) | EP4357356A3 (enExample) |
| JP (1) | JP2023501204A (enExample) |
| CN (1) | CN114746112A (enExample) |
| AU (1) | AU2020384926B2 (enExample) |
| BR (1) | BR112022009100A2 (enExample) |
| CA (2) | CA3153470A1 (enExample) |
| DK (1) | DK4021487T5 (enExample) |
| ES (1) | ES2971929T3 (enExample) |
| FI (1) | FI4021487T3 (enExample) |
| HR (1) | HRP20240116T1 (enExample) |
| HU (1) | HUE065075T2 (enExample) |
| LT (1) | LT4021487T (enExample) |
| MX (1) | MX2022005704A (enExample) |
| PL (1) | PL4021487T3 (enExample) |
| RS (1) | RS65262B1 (enExample) |
| SI (1) | SI4021487T1 (enExample) |
| SM (1) | SMT202400048T1 (enExample) |
| WO (1) | WO2021094562A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110049774A (zh) | 2016-10-07 | 2019-07-23 | 恩特罗姆公司 | 肿瘤相关抗原表位的小型生物群序列变体 |
| IL302345B2 (en) | 2016-10-07 | 2024-12-01 | Enterome S A | Immunogenic compounds for cancer therapy |
| CN110022894B (zh) | 2016-10-07 | 2024-01-19 | 恩特罗姆公司 | 用于癌症疗法的免疫原性化合物 |
| DK3773689T5 (da) | 2018-04-11 | 2024-08-19 | Enterome S A | Antigene peptider til forebyggelse og behandling af kræft |
| JP2025081784A (ja) * | 2022-03-01 | 2025-05-28 | ｂｉｔＢｉｏｍｅ株式会社 | アミノ酸残基配列を同定するための方法，プログラム及び記録媒体 |
| US20260041748A1 (en) * | 2022-07-29 | 2026-02-12 | Lg Chem, Ltd. | Recombinant fusion protein for antigen delivery and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| DE68907045T2 (de) | 1989-01-17 | 1993-12-02 | Eniricerche Spa | Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind. |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| US5635363A (en) | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| JP2002539273A (ja) | 1999-03-19 | 2002-11-19 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
| CA2365914A1 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| FR2798128B1 (fr) | 1999-09-06 | 2001-11-16 | Inst Nat Sante Rech Med | Moyens de detection et de purification de populations lymphocytaires t cd8+ specifiques de peptides presentes dans le contexte hla |
| US7812116B2 (en) * | 2003-07-03 | 2010-10-12 | Rush University Medical Center | Immunogenic peptides |
| RS53872B2 (sr) | 2008-05-14 | 2018-06-29 | Immatics Biotechnologies Gmbh | Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana |
| WO2013040142A2 (en) * | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| WO2013101690A1 (en) | 2011-12-29 | 2013-07-04 | modeRNA Therapeutics | Modified mrnas encoding cell-penetrating polypeptides |
| EP2639299A1 (en) | 2012-03-16 | 2013-09-18 | Invectys | Universal cancer peptides derived from telomerase |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| AU2017254477A1 (en) * | 2016-04-18 | 2018-11-01 | Jennifer G. ABELIN | Improved HLA epitope prediction |
| CN106008695A (zh) * | 2016-06-19 | 2016-10-12 | 苏州普罗达生物科技有限公司 | 一种关于cd19免疫原多肽及其用途 |
| IL302345B2 (en) * | 2016-10-07 | 2024-12-01 | Enterome S A | Immunogenic compounds for cancer therapy |
| EP3679065A4 (en) * | 2017-09-06 | 2021-05-19 | California Institute of Technology | SIGNALING AND ANTIGEN-PRESENTING BIFUNCTIONAL RECEPTORS (SABR) |
| JP7232825B2 (ja) * | 2017-10-09 | 2023-03-03 | エンテローム エスエー | 腫瘍関連抗原エピトープの微生物叢（ｍｉｃｒｏｂｉｏｔａ）配列変異体 |
| DK3773689T5 (da) * | 2018-04-11 | 2024-08-19 | Enterome S A | Antigene peptider til forebyggelse og behandling af kræft |
| WO2020072700A1 (en) * | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
-
2020
- 2020-11-13 LT LTEPPCT/EP2020/082101T patent/LT4021487T/lt unknown
- 2020-11-13 PL PL20804279.6T patent/PL4021487T3/pl unknown
- 2020-11-13 CA CA3153470A patent/CA3153470A1/en active Pending
- 2020-11-13 CA CA3290212A patent/CA3290212A1/en active Pending
- 2020-11-13 HR HRP20240116TT patent/HRP20240116T1/hr unknown
- 2020-11-13 HU HUE20804279A patent/HUE065075T2/hu unknown
- 2020-11-13 JP JP2022525171A patent/JP2023501204A/ja active Pending
- 2020-11-13 AU AU2020384926A patent/AU2020384926B2/en active Active
- 2020-11-13 CN CN202080083161.5A patent/CN114746112A/zh active Pending
- 2020-11-13 EP EP23220228.3A patent/EP4357356A3/en active Pending
- 2020-11-13 DK DK20804279.6T patent/DK4021487T5/da active
- 2020-11-13 SI SI202030352T patent/SI4021487T1/sl unknown
- 2020-11-13 SM SM20240048T patent/SMT202400048T1/it unknown
- 2020-11-13 EP EP20804279.6A patent/EP4021487B1/en active Active
- 2020-11-13 ES ES20804279T patent/ES2971929T3/es active Active
- 2020-11-13 FI FIEP20804279.6T patent/FI4021487T3/fi active
- 2020-11-13 WO PCT/EP2020/082101 patent/WO2021094562A2/en not_active Ceased
- 2020-11-13 BR BR112022009100A patent/BR112022009100A2/pt unknown
- 2020-11-13 RS RS20240132A patent/RS65262B1/sr unknown
- 2020-11-13 MX MX2022005704A patent/MX2022005704A/es unknown
-
2022
- 2022-05-02 US US17/734,694 patent/US11759508B2/en active Active
-
2023
- 2023-07-19 US US18/354,966 patent/US20240033335A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4357356A2 (en) | 2024-04-24 |
| US20220323561A1 (en) | 2022-10-13 |
| HRP20240116T1 (hr) | 2024-04-12 |
| US11759508B2 (en) | 2023-09-19 |
| FI4021487T3 (fi) | 2024-02-06 |
| JP2023501204A (ja) | 2023-01-18 |
| SMT202400048T1 (it) | 2024-03-13 |
| ES2971929T3 (es) | 2024-06-10 |
| EP4357356A3 (en) | 2024-07-31 |
| PL4021487T3 (pl) | 2024-04-15 |
| CA3153470A1 (en) | 2021-05-20 |
| CN114746112A (zh) | 2022-07-12 |
| CA3290212A1 (en) | 2026-03-02 |
| RS65262B1 (sr) | 2024-03-29 |
| DK4021487T3 (da) | 2024-02-12 |
| AU2020384926B2 (en) | 2025-09-18 |
| SI4021487T1 (sl) | 2024-03-29 |
| EP4021487B1 (en) | 2023-12-27 |
| HUE065075T2 (hu) | 2024-04-28 |
| AU2020384926A1 (en) | 2022-04-28 |
| EP4021487A2 (en) | 2022-07-06 |
| WO2021094562A2 (en) | 2021-05-20 |
| WO2021094562A3 (en) | 2021-09-30 |
| MX2022005704A (es) | 2022-06-08 |
| US20240033335A1 (en) | 2024-02-01 |
| BR112022009100A2 (pt) | 2022-07-26 |
| LT4021487T (lt) | 2024-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3773689T3 (da) | Antigene peptider til forebyggelse og behandling af kræft | |
| DK4021487T3 (da) | Antigene peptider til forebyggelse og behandling af b-celle malignitet | |
| DK4028010T3 (da) | Vs-6063 i kombination med ch5126766 til behandlingen af kræft | |
| DK3735295T3 (da) | Forbedrede peptidfarmaceutika til behandling af nash og andre lidelser | |
| ZA202007649B (en) | Virus and antigen purification and conjugation | |
| IL283200A (en) | Combination treatment of nafld and nash | |
| DK3504210T3 (da) | 7-substituerede sulfonimidoylpurinonforbindelser til behandling og forebyggelse af virusinfektion | |
| EP3870576C0 (en) | BENZOPYRAZOLE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | |
| DK3807316T3 (da) | Sammensætninger og fremgangsmåder til behandling af cancer | |
| DK3388075T3 (da) | Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod forskellige tumorer | |
| DK3720879T3 (da) | Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer | |
| IL292599A (en) | tmem219 antibodies and medical uses thereof | |
| SG11202011170YA (en) | Antibodies against lif and dosage forms thereof | |
| IL283039A (en) | Immunogenic compositions for treatment of hepatitis b | |
| IL281997A (en) | Combined treatment for the treatment of uveal melanoma | |
| DK3630112T3 (da) | Kombination af regorafenib og nivolumab til behandling af cancer | |
| DK4218788T3 (da) | Peptider til anvendelse ved behandling af ikke-alkoholisk steatohepatitis | |
| DK3349731T3 (da) | Kombination af topoisomerase-i-inhibitorer med immunoterapi til behandlingen af kræft | |
| DK4054582T3 (da) | Terapeutiske kombinationer af acalabrutinib og capivasertib til behandling af b-celle-maligniteter | |
| DK4073051T3 (da) | Fremgangsmåde og mellemstof til fremstilling af oxetan-2-ylmethanamin | |
| DK4061299T3 (da) | Indretning til behandling af cellulitis | |
| DK3897697T3 (da) | Peptider til behandling og forebyggelse af diabetes og forbundne lidelser | |
| DK3618853T3 (da) | Fibrinogen-gamma-prime-varianter til anvendelse til behandling af en infektion | |
| EP3773058A4 (en) | DISCREET ELBOW BRACKET | |
| PT4021487T (pt) | Péptidos antigénicos para prevenir e tratar neoplasia maligna de células b |